Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 19/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 8/20 | 0.50 |
| ▸ | PLA2G10 | O15496 | 6/20 | 0.50 |
| ▸ | PLA2G2E | Q9NZK7 | 6/20 | 0.50 |
| ▸ | PLA2G5 | P39877 | 5/20 | 0.50 |
| ▸ | PLA2G2F | Q9BZM2 | 3/20 | 0.48 |
| ▸ | PLA2G2D | Q9UNK4 | 3/20 | 0.48 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.48 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.48 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.48 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.48 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29862408 | 1.00 | PLA2G2A (0.50) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL6695557 | 0.99 | PLA2G2A (0.52) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL7966224 | 0.96 | PLA2G2A (0.54) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL7966060 | 0.95 | PLA2G2A (0.56) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL7964957 | 0.95 | PLA2G2A (0.48) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL29862573 | 0.94 | PLA2G2A (0.54) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL818840 | 0.94 | PLA2G2A (0.54) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL7966826 | 0.93 | PLA2G2A (0.47) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL7966034 | 0.93 | PLA2G2A (0.48) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL7966757 | 0.93 | PLA2G2A (0.48) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | LOH ANDREW (US) | 2004-06-10 | — | — | US | claimed |
| EP-0952149-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | claimed |
| JP-2004503586-A | — | — | 2004-02-05 | — | — | JP | claimed |
| EP-1303262-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | claimed |
| US-6514984-B1 | Human non-pancreatic secretory phospholipase A2 inhibitors | ELI LILLY AND COMPANY | 2003-02-04 | — | — | US | claimed |
| EP-1259260-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | ELI LILLY AND COMPANY (US) | 2002-11-27 | — | — | EP | claimed |
| WO-2002005796-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | claimed |
| WO-2001049323-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | ELI LILLY AND COMPANY (US) | 2001-07-12 | — | — | WO | claimed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | claimed |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | OPHIREX, INC (US) | 2026-03-03 | — | — | US | disclosed |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | OPHIREX, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | OPHIREX, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| EP-3448378-B1 | PLA2 AND HMG-COA INHIBITORS FOR TREATMENT OF PATHOLOGICAL CONDITIONS CAUSING HEMOLYSIS, CEREBRAL EDEMA, AND ACUTE KIDNEY INJURY | OPHIREX INC (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-116585306-A | PLA2 inhibitors for immediate treatment of hymenoptera toxicity and other conditions due to histamine release | 奥菲瑞克斯股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-1043991-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 2000-10-18 | — | — | EP | disclosed |
| EP-1011670-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 2000-06-28 | — | — | EP | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |
| WO-1999025340-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1999009978-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | PLA2G12A, PLA2G2E, PLA2G3 | PLA2G2A 24/4885PLA2G1B 9/4885PLA2G10 10/4885 |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | PLA2G4A, PLA2G12A, PLA2G6 | PLA2G2A 4/4885PLA2G1B 6/4885PLA2G10 11/4885 |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | PLA2G12A, PLA2G3, PLA2G1B | PLA2G2A 19/4885PLA2G1B 3/4885PLA2G10 9/4885 |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | PLA2G12A, PLA2G2D, PLAAT2 | PLA2G2A 12/4885PLA2G1B 11/4885PLA2G10 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.